G

Galderma

Independent dermatology company delivering skincare therapies

Product Master Data Coordinator

Full-TimeUpdated Deadline 11/4/26
No salary listed
Mid
Bachelor's
Bogotá, Bogota, Colombia
In Person
Data & AnalyticsData Management

About the job

Requirements
  • Bachelor's degree in Industrial Engineering, Supply Chain Management, Business Administration, Data Analytics, Information Systems, or a related field.
  • Experience in Master Data Management, Supply Chain, Product Management, Data Governance, or related areas.
  • Experience supporting cross-functional projects and product launch initiatives.
  • Exposure to supply chain processes, product lifecycle management, or business operations.
  • Experience working with large datasets and reporting tools.
  • Advanced Excel skills.
  • Power BI dashboard development and reporting skills.
  • Data analysis and reporting skills.
  • Process automation and continuous improvement skills.
  • Knowledge of Master Data Governance principles.
  • Experience with ERP systems; SAP is preferred.
  • Strong analytical skills and attention to detail.
  • Project management and coordination capabilities.
  • Ability to work effectively across multiple functions and stakeholders.
  • Strong problem-solving and process improvement capabilities.
  • Organizational and communication skills.
  • Ability to manage multiple priorities in a fast-paced environment.
Responsibilities
  • Ensure the accuracy, integrity, and completeness of product master data across the region.
  • Create, maintain, and update product information within relevant systems.
  • Manage SKU creation, modifications, product extensions, and product discontinuations.
  • Monitor and correct data inconsistencies, stock-related discrepancies, and master data issues.
  • Maintain governance standards and data quality controls for product information.
  • Support regional and cross-functional projects involving new product introductions and portfolio changes.
  • Coordinate master data requirements throughout each project stage.
  • Collaborate with Supply Chain, Finance, Marketing, and Commercial teams to ensure all required product information is available and validated.
  • Ensure products are fully set up with the necessary costing, supply, logistics, and commercial information before launch.
  • Track project milestones and ensure master data deliverables are completed on time.
  • Develop and maintain KPIs related to master data quality, product portfolio management, and supply performance.
  • Support the consolidation and analysis of key business metrics, including forecasts, sales performance, inventory, and product portfolio indicators.
  • Generate reports and dashboards to support business decision-making.
  • Identify opportunities for process improvements and increased operational efficiency.
  • Promote data governance best practices across the organization.
  • Drive initiatives focused on data quality, standardization, automation, and process optimization.
  • Support the development of automated reporting and data management solutions.
  • Partner with stakeholders to improve data-related processes and controls.
Desired Qualifications
  • Experience with SAP ERP systems.

About the company

G

Galderma

View
Website

Dermatology-focused medicines and skincare products are Galderma’s core business, including prescription therapies, over-the-counter skincare, and injectable aesthetics. It combines pharmaceutical R&D with consumer skin insights to develop treatments that address skin conditions, improve appearance, and support overall skin health. Unlike many peers, Galderma operates as an independent, publicly traded dermatology specialist with a long history in skin science, spanning prescription, OTC, and aesthetic segments. Its goal is to be a global leader in science-based solutions for skin conditions, growing across therapeutic dermatology, injectables, and skincare worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Lausanne, Switzerland

Founded

1981

Get referred to Galderma

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales hit $3.134 billion, up 24.6%, and guidance rose to 19-21%.
  • Galderma opened Miami headquarters in August 2026, targeting 200 staff and stronger U.S. selling.
  • The $650 million U.S. manufacturing buildout through 2030 supports supply and tariff resilience.

What critics are saying

  • FDA's July 1, 2026 Relfydess CRL pushes U.S. launch toward 2027.
  • AbbVie's Allergan Aesthetics still dominates Botox and Juvéderm, keeping Galderma behind.
  • Nemluvio and Relfydess depend on execution in the U.S.; another regulatory miss crushes momentum.

What makes Galderma unique

  • Relfydess, approved in 33 markets by July 2026, gives Galderma a proprietary neuromodulator.
  • Galderma spans Cetaphil, Restylane, Sculptra, Nemluvio, and Dysport across dermatology categories.
  • The September 21, 2026 SMI inclusion validates its scale and Swiss capital-market credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

0%

1 year growth

-1%

2 year growth

-1%
Finanzen.net
Oct 30th, 2026
SMI-listed Galderma stock: how much profit an investment in Galderma a year ago would have generated.

SMI-listed Galderma stock: how much profit an investment in Galderma a year ago would have generated. 10/30/26, 10:00 a.m. That would have been the profit from an early investment in Galderma shares. On 10/30/2025, Galderma shares were traded on the SWX exchange. Galderma shares ended that trading day at CHF 147.50. If an investor had invested CHF 1,000 in the Galderma share at that time, they would now hold 6.780 Galderma shares. Since the value of one security on 10/29/2026 was CHF 189.70 (closing level), the original investment would now be worth CHF 1,286.10. That corresponds to an increase of 28.61 percent. Galderma's market value recently amounted to CHF 44.22 billion. The first trading day of the Galderma share on the SWX exchange was 03/22/2024. The Galderma share began its first trading day at CHF 61.00. Please note that stock splits and dividend payments are not taken into account in the above calculation. Finanzen.net editorial team Selected leveraged products on Galderma. With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired leverage and we will show you suitable open-end products on Galderma. Name | Leverage | KO | Issuer Turbo long on Galderma Group AG | 4.51 | 149.10 | Morgan Stanley Mini future long on Galderma Group AG | 4.22 | 160.18 | Morgan Stanley Turbo long on Galderma Group AG | 4.01 | 144.09 | Morgan Stanley Mini future long on Galderma Group AG | 3.56 | 150.69 | Morgan Stanley Turbo long on Galderma Group AG | 3.53 | 137.08 | Morgan Stanley You can obtain the base prospectus as well as the final terms and the key information documents here: MN6T0E, MR9T88, MN617V, MR85HB, MM4UH9. Please also note the further information** on this advertisement. Risk notice: on average, 7 out of 10 retail investors suffer losses when trading turbo certificates. Turbo certificates are highly risky products and are not suitable for long-term investment strategies.

Yahoo Finance
Oct 26th, 2026
Galderma launches ALASTIN eye complex with TriHex+ for the full eye area

Galderma (SIX: GALD) has launched ALASTIN Restorative Eye Complex with TriHex+ in the US. The skincare product targets signs of ageing across the upper eyelid, under-eye area, and crow's feet. The formula pairs ALASTIN's TriHex Technology with a proprietary peptide, Octapeptide-45, to support collagen, elastin, and hyaluronic acid (HA) production. It also adds Acetyl Tetrapeptide-2 and a dill and blackberry blend. In a clinical evaluation of 29 patients aged 35 to 70, investigators found a 30.13% improvement in crow's feet fine lines and a 33.63% improvement in under-eye puffiness at Week 12. Upper-eyelid fine lines fell 21.62%. It is the third product in the TriHex+ range. It will initially be sold only in the US, through authorised healthcare providers and provider microsites.

Yahoo Finance
Oct 23rd, 2026
China approves Galderma's Relfydess, first ready-to-use liquid neuromodulator, for frown lines

Galderma's Relfydess has won approval in China for the temporary improvement of moderate-to-severe frown lines in adults, the Swiss company announced on October 23, 2026. The country's National Medical Products Administration (NMPA) cleared the product, which Galderma calls the first and only ready-to-use liquid neuromodulator. Approval rests on a local phase III trial in China and the global READY trials, which had more than 2,300 participants. In the China study, 72.4% of patients saw a at least two-grade improvement at month one, against 1.6% on placebo. In READY-1, 39% reported improvement from day one, and up to 75% kept results for six months. Relfydess is now authorised in more than 35 markets, including the EU, the UK, and Australia.

Yahoo Finance
Oct 22nd, 2026
Galderma lifts 2026 sales growth guidance to 22.5%-23.5% after 26% Q3 jump

Swiss dermatology group Galderma raised its 2026 sales growth guidance to 22.5% to 23.5% at constant currency, up from 19% to 21%. A company-compiled analyst forecast pointed to 21.4%. Third-quarter growth was 26.0%, beating the expected 19.9%. Sales for the first nine months rose 25.1% to $4.77 billion, driven mainly by higher volumes. Galderma kept its core EBITDA margin target at about 26% as it keeps spending to support growth. Chief executive Flemming Ornskov said "robust demand for our differentiated, premium portfolio continues to drive growth." The guidance excludes the $1.5 billion all-cash purchase of ZO Skin Health, expected to close in the fourth quarter or early 2027. Galderma said the deal should slightly reduce its 2027 core EBITDA margin.

WZUU
Oct 22nd, 2026
Galderma lifts outlook for second quarter in a row after sales jump.

Galderma lifts outlook for second quarter in a row after sales jump. By Thomson Reuters Oct 22, 2026 | 2:22 AM ZURICH, Oct 22 (Reuters) - Swiss skincare company Galderma raised its full-year sales guidance on Thursday for the second time in two quarters after strong demand for its therapeutic dermatology products drove robust growth in the first nine months of the year. The company reported net sales of $4.77 billion for January to September, up 25.1% from a year earlier. Third-quarter sales growth was 26%. Galderma raised its full-year net sales growth forecast to between 22.5% and 23.5% from 19% to 21%. Its shares rose as much as 5.8% in morning trade. The stock has more than tripled in value since the company listed on the Swiss stock exchange in March 2024. Injectable aesthetics sales rose 13.2% in the first nine months, while dermatological skincare sales increased 16.2%. Therapeutic dermatology sales jumped 64.4%, helped in part by strong demand for its Nemluvio product. CEO Flemming Ornskov said the company was assessing the impact of so-called Section 232 tariffs that took effect in the US in September, including on Nemluvio. With companies facing higher costs from disruptions linked to the US-Iran conflict, pricing is under close scrutiny across the industry. Ornskov noted that competitors in markets such as China and India operated from a lower cost base. "But given that we are segmented more to premium, we're holding up really well," he said. (Writing by Dave Graham. Editing by Linda Pasquini and Mark Potter)